Department of Neurosurgery, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, China.
Department of Neuro-Psychiatric Institute, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, China.
Nanomedicine (Lond). 2024;19(26):2229-2249. doi: 10.1080/17435889.2024.2395238. Epub 2024 Sep 23.
Glioblastoma (GBM), a highly invasive type of brain tumor located within the central nervous system, manifests a median survival time of merely 14.6 months. Radiotherapy kills tumor cells through focused high-energy radiation and has become a crucial treatment strategy for GBM, especially in cases where surgical resection is not viable. However, the presence of radioresistant tumor cells limits its clinical effectiveness. Radioresistance is a key factor of treatment failure, prompting the development of various therapeutic strategies to overcome this challenge. With the rapid development of nanomedicine, nanoradiosensitizers provide a novel approach to enhancing the effectiveness of radiotherapy. In this review, we discuss the reasons behind GBM radio-resistance and the mechanisms of radiotherapy sensitization. Then we summarize the primary types of nanoradiosensitizers and recent progress in their application for the radiosensitization of GBM. Finally, we elucidate the factors influencing their practical implementation, along with the challenges and promising prospects associated with multifunctional nanoradiosensitizers.
胶质母细胞瘤(GBM)是一种位于中枢神经系统内的高度侵袭性脑肿瘤,中位生存时间仅为 14.6 个月。放疗通过聚焦高能射线杀死肿瘤细胞,已成为 GBM 的重要治疗策略,特别是在手术切除不可行的情况下。然而,存在放射抵抗的肿瘤细胞限制了其临床效果。放射抵抗是治疗失败的关键因素,促使人们开发各种治疗策略来克服这一挑战。随着纳米医学的快速发展,纳米放射增敏剂为提高放疗效果提供了一种新方法。在这篇综述中,我们讨论了 GBM 放射抵抗的原因和放射增敏的机制。然后总结了主要类型的纳米放射增敏剂及其在 GBM 放射增敏中的应用的最新进展。最后,我们阐明了影响其实际应用的因素,以及多功能纳米放射增敏剂所面临的挑战和有前景的方面。
Nanomedicine (Lond). 2024
Phys Med Biol. 2025-6-20
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024
Cochrane Database Syst Rev. 2021-5-4
Cochrane Database Syst Rev. 2020-3-23